Skip to content

Study · Not a test of the peptide alone · 2009

4 results

Effects of an LL-37-derived antimicrobial peptide in an animal model of biofilm Pseudomonas sinusitis.

Chennupati SK, Chiu AG, Tamashiro E, Banks CA, Cohen MB, Bleier BS, Kofonow JM, Tam E, Cohen NA

American journal of rhinology & allergy1 Jan 2009Cited by 67 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, LL-37 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking LL-37.

  1. 01AnimalNot a test of LL-37 aloneAnimal study (in vivo)Efficacy outcome

    In rabbits with Pseudomonas aeruginosa sinusitis, the 24 amino acid LL‑37-derived peptide at 2.5 mg/mL significantly lowered bacterial colony-forming units after 10 days of irrigation.

    In plain wordsIn rabbits with sinus infection, a peptide made from LL‑37 at 2.5 mg/mL lowered bacterial counts after 10 days.

    Peptide
    LL-37
    Outcome
    DecreaseBacterial CFU in nasal diluent after 10 days
    Study

    rabbitn = 30

    Pseudomonas aeruginosa (PAO-1) biofilm sinusitis model with irrigating catheters
    Comparator
    Carrier solution without peptide
    Outcome group
    Infection and antimicrobial activity · Infection

    Source sentences

    Summary
    Topical tobramycin at 400x minimum inhibitory concentration and 2.5 mg/mL of peptide were effective in significantly lowering CFUs after 10 days of irrigation.
    2 context sentences
    Summary · context
    Five groups of six New Zealand rabbits were each infected with P. aeruginosa (PAO-1) and fitted with irrigating catheters 7 days later.
    Summary · context
    Each group was instilled with either one of three different concentrations of peptide, a positive control of topical tobramycin, or the carrier solution without the peptide once a day for 10 days.

    In this study, LL-37 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LL-37.

  2. 02AnimalNot a test of LL-37 aloneAnimal study (in vivo)Safety outcome

    In rabbits with Pseudomonas aeruginosa sinusitis, the LL‑37-derived peptide increased histological signs of inflammation in sinus mucosa and bone in a dose-dependent manner.

    In plain wordsIn rabbits, higher doses of the LL‑37-derived peptide caused more inflammation in sinus lining and bone.

    Peptide
    LL-37
    Outcome
    IncreaseMucosal and bone inflammation on histology
    Study

    rabbitn = 30

    Pseudomonas aeruginosa (PAO-1) biofilm sinusitis model with irrigating catheters
    Comparator
    Carrier solution without peptide
    Outcome group
    Inflammation markers · Infection

    Source sentences

    Summary
    Histological evaluation showed increased signs of inflammation in a dose-dependent manner within mucosa and bone of the groups receiving the peptide.
    2 context sentences
    Summary · context
    Five groups of six New Zealand rabbits were each infected with P. aeruginosa (PAO-1) and fitted with irrigating catheters 7 days later.
    Summary · context
    Each group was instilled with either one of three different concentrations of peptide, a positive control of topical tobramycin, or the carrier solution without the peptide once a day for 10 days.

    In this study, LL-37 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LL-37.

  3. 03AnimalNot a test of LL-37 aloneAnimal study (in vivo)Safety outcome

    In rabbits with Pseudomonas aeruginosa sinusitis, the LL‑37-derived peptide caused ciliary loss on scanning electron microscopy in a dose-dependent manner.

    In plain wordsIn rabbits, higher doses of the LL‑37-derived peptide caused more loss of cilia in the sinus lining.

    Peptide
    LL-37
    Outcome
    IncreaseCiliary loss on SEM
    Study

    rabbitn = 30

    Pseudomonas aeruginosa (PAO-1) biofilm sinusitis model with irrigating catheters
    Comparator
    Carrier solution without peptide
    Outcome group
    Adverse events · Respiratory

    Source sentences

    Summary
    SEM analysis showed ciliary loss in a dose-dependent manner.
    2 context sentences
    Summary · context
    Five groups of six New Zealand rabbits were each infected with P. aeruginosa (PAO-1) and fitted with irrigating catheters 7 days later.
    Summary · context
    Each group was instilled with either one of three different concentrations of peptide, a positive control of topical tobramycin, or the carrier solution without the peptide once a day for 10 days.

    In this study, LL-37 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LL-37.

  4. 04AnimalNot a test of LL-37 aloneAnimal study (in vivo)Efficacy outcome

    In rabbits with Pseudomonas aeruginosa sinusitis, biofilms were present in all groups except the group with the highest peptide concentration and the tobramycin group.

    In plain wordsIn rabbits with sinus infection, biofilms were absent only with the highest peptide dose and with tobramycin.

    Peptide
    LL-37
    Outcome
    DecreaseBiofilm presence on SEM
    Study

    rabbitn = 30

    Pseudomonas aeruginosa (PAO-1) biofilm sinusitis model with irrigating catheters
    Comparator
    Carrier solution without peptide
    Outcome group
    Infection and antimicrobial activity · Infection

    Source sentences

    Summary
    Biofilms were present in all groups except for the highest concentration of peptide and tobramycin.
    2 context sentences
    Summary · context
    Five groups of six New Zealand rabbits were each infected with P. aeruginosa (PAO-1) and fitted with irrigating catheters 7 days later.
    Summary · context
    Each group was instilled with either one of three different concentrations of peptide, a positive control of topical tobramycin, or the carrier solution without the peptide once a day for 10 days.

    In this study, LL-37 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LL-37.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:58 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.